{{Rsnum
|rsid=6332
|Gene=NTF3
|Chromosome=12
|position=5494466
|Orientation=plus
|ReferenceAllele=G
|GMAF=0.4917
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NTF3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 24.8 | 57.5 | 17.7
| HCB | 21.2 | 51.1 | 27.7
| JPT | 16.8 | 47.8 | 35.4
| YRI | 32.0 | 46.3 | 21.8
| ASW | 38.6 | 45.6 | 15.8
| CHB | 21.2 | 51.1 | 27.7
| CHD | 24.8 | 49.5 | 25.7
| GIH | 27.0 | 44.0 | 29.0
| LWK | 28.2 | 42.7 | 29.1
| MEX | 17.2 | 44.8 | 37.9
| MKK | 26.3 | 50.0 | 23.7
| TSI | 22.5 | 47.1 | 30.4
| HapMapRevision=28
}}{{PMID|18428117}} Adult [[attention deficit hyperactivity disorder]] ([[ADHD]]) 143 high-risk male subjects . [[rs6332]] showed a trend toward an association between the A-allele and increased scores

{{PMID Auto
|PMID=20576502
|Title=Neurotrophin-3 gene, intelligence, and selective attention deficit in a Korean sample with attention-deficit/hyperactivity disorder
}}

{{PMID Auto
|PMID=23075484
|Title=Association between Neurotrophin-3 Polymorphisms and Executive Function in Japanese Patients with Amnestic Mild Cognitive Impairment and Mild Alzheimer Disease
}}

{{PMID Auto
|PMID=23471121
|Title=Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/ hyperactivity disorder
}}

{{PMID Auto
|PMID=23872233
|Title=The relationship between the presence of ADHD and certain candidate gene polymorphisms in a Turkish sample
}}

{{PMID Auto
|PMID=24174922
|Title=Genetic Association between Neurotrophin-3 Polymorphisms and Alzheimer's Disease in Japanese Patients
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}